Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
3 "Dae Joon Kim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
Lung and Thoracic cancer
The Role of Adjuvant Therapy Following Surgical Resection of Small Cell Lung Cancer: A Multi-Center Study
Seong Yong Park, Samina Park, Geun Dong Lee, Hong Kwan Kim, Sehoon Choi, Hyeong Ryul Kim, Yong-Hee Kim, Dong Kwan Kim, Seung-Il Park, Tae Hee Hong, Yong Soo Choi, Jhingook Kim, Jong Ho Cho, Young Mog Shim, Jae Ill Zo, Kwon Joong Na, In Kyu Park, Chang Hyun Kang, Young-Tae Kim, Byung Jo Park, Chang Young Lee, Jin Gu Lee, Dae Joon Kim, Hyo Chae Paik
Cancer Res Treat. 2023;55(1):94-102.   Published online June 9, 2022
DOI: https://doi.org/10.4143/crt.2022.290
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This multi-center, retrospective study was conducted to evaluate the long-term survival in patients who underwent surgical resection for small cell lung cancer (SCLC) and to identify the benefit of adjuvant therapy following surgery.
Materials and Methods
The data of 213 patients who underwent surgical resection for SCLC at four institutions were retrospectively reviewed. Patients who received neoadjuvant therapy or an incomplete resection were excluded.
Results
The mean patient age was 65.29±8.93 years, and 184 patients (86.4%) were male. Lobectomies and pneumonectomies were performed in 173 patients (81.2%), and 198 (93%) underwent systematic mediastinal lymph node dissections. Overall, 170 patients (79.8%) underwent adjuvant chemotherapy, 42 (19.7%) underwent radiotherapy to the mediastinum, and 23 (10.8%) underwent prophylactic cranial irradiation. The median follow-up period was 31.08 months (interquartile range, 13.79 to 64.52 months). The 5-year overall survival (OS) and disease-free survival were 53.4% and 46.9%, respectively. The 5-year OS significantly improved after adjuvant chemotherapy in all patients (57.4% vs. 40.3%, p=0.007), and the survival benefit of adjuvant chemotherapy was significant in patients with negative node pathology (70.8% vs. 39.7%, p=0.004). Adjuvant radiotherapy did not affect the 5-year OS (54.6% vs. 48.5%, p=0.458). Age (hazard ratio [HR], 1.032; p=0.017), node metastasis (HR, 2.190; p < 0.001), and adjuvant chemotherapy (HR, 0.558; p=0.019) were associated with OS.
Conclusion
Adjuvant chemotherapy after surgical resection in patients with SCLC improved the OS, though adjuvant radiotherapy to the mediastinum did not improve the survival or decrease the locoregional recurrence rate.

Citations

Citations to this article as recorded by  
  • Application of postoperative adjuvant radiotherapy in limited-stage small cell lung cancer: A systematic review and meta-analysis
    Chuanhao Zhang, Genghao Zhao, Huajian Wu, Jianing Jiang, Wenyue Duan, Zhijun Fan, Zhe Wang, Ruoyu Wang
    Radiotherapy and Oncology.2024; 193: 110123.     CrossRef
  • A 15-Gene-Based Risk Signature for Predicting Overall Survival in SCLC Patients Who Have Undergone Surgical Resection
    Sevcan Atay
    Cancers.2023; 15(21): 5219.     CrossRef
  • 5,829 View
  • 143 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Optimal Adjuvant Treatment for Curatively Resected Thoracic Esophageal Squamous Cell Carcinoma: A Radiotherapy Perspective
Kyung Hwan Kim, Jee Suk Chang, Ji Hye Cha, Ik Jae Lee, Dae Joon Kim, Byoung Chul Cho, Kyung Ran Park, Chang Geol Lee
Cancer Res Treat. 2017;49(1):168-177.   Published online June 23, 2016
DOI: https://doi.org/10.4143/crt.2016.142
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to evaluate the benefits of adjuvant treatment for curatively resected thoracic esophageal squamous cell carcinoma (ESCC) and determine the optimal adjuvant treatments.
Materials and Methods
One hundred ninety-five patients who underwent a curative resection for thoracic ESCC between 1994 and 2014 were reviewed retrospectively. Postoperatively, the patients received no adjuvant treatment (no-adjuvant group, n=68), adjuvant chemotherapy (AC group, n=62), radiotherapy (RT group, n=41), or chemoradiotherapy (CRT group, n=24). Chemotherapy comprised cisplatin and 5-fluorouracil administration every 3 weeks. The median RT dose was 45.0 Gy (range, 34.8 to 59.4 Gy). The overall survival (OS), disease-free survival (DFS), locoregional recurrence (LRR), and distant metastasis (DM) rates were estimated.
Results
At a median follow-up duration of 42.2 months (range, 6.3 to 215.2 months), the 5-year OS and DFS were 37.6% and 31.4%, respectively. After adjusting for other clinicopathologic variables, the AC and CRT groups had a significantly better OS and DFS compared to the no-adjuvant group (p < 0.05). The LRR rate was significantly lower in the RT and CRT groups than in the no-adjuvant group (p < 0.05), whereas no significant difference was observed in the AC group. In the no-adjuvant and AC groups, 25% of patients received high-dose salvage RT due to LRR. The DM rates were similar. The anastomotic stenosis and leakage were similar in the treatment groups.
Conclusion
Adjuvant treatment might prolong survival after an ESCC resection, and RT contributes to a reduction of the LRR. Overall, the risks and benefits should be weighed properly when selecting the optimal adjuvant treatment.

Citations

Citations to this article as recorded by  
  • The Society of Thoracic Surgeons/American Society for Radiation Oncology Updated Clinical Practice Guidelines on Multimodality Therapy for Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
    Stephanie G. Worrell, Karyn A. Goodman, Nasser K. Altorki, Jonathan B. Ashman, Traves D. Crabtree, Jennifer Dorth, Scott Firestone, David H. Harpole, Wayne L. Hofstetter, Theodore S. Hong, Kalie Kissoon, Geoffrey Y. Ku, Daniela Molena, Joel E. Tepper, Tho
    Practical Radiation Oncology.2024; 14(1): 28.     CrossRef
  • The Society of Thoracic Surgeons/American Society for Radiation Oncology Updated Clinical Practice Guidelines on Multimodality Therapy for Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
    Stephanie G. Worrell, Karyn A. Goodman, Nasser K. Altorki, Jonathan B. Ashman, Traves D. Crabtree, Jennifer Dorth, Scott Firestone, David H. Harpole, Wayne L. Hofstetter, Theodore S. Hong, Kalie Kissoon, Geoffrey Y. Ku, Daniela Molena, Joel E. Tepper, Tho
    The Annals of Thoracic Surgery.2024; 117(1): 15.     CrossRef
  • Esophageal cancer: Treatment challenges and controversies
    Piyush Kumar, Ankita Mehta
    Journal of Current Oncology.2021; 4(1): 41.     CrossRef
  • Radical esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma followed by adjuvant radiotherapy with or without chemotherapy: Which is more beneficial?
    Bingwen Zou, Yan Tu, Duwen Liao, Yong Xu, Jin Wang, Meijuan Huang, Li Ren, Jiang Zhu, Youling Gong, Yongmei Liu, Lin Zhou, Xiaojuan Zhou, Feng Peng, You Lu
    Thoracic Cancer.2020; 11(3): 631.     CrossRef
  • A meta-analysis on surgery with or without postoperative radiotherapy to treat squamous cell esophageal carcinoma
    Hao-Nan Lin, Long-Qi Chen, Qi-Xin Shang, Yong Yuan, Yu-Shang Yang
    International Journal of Surgery.2020; 80: 184.     CrossRef
  • Homeobox D10, a tumor suppressor, inhibits the proliferation and migration of esophageal squamous cell carcinoma
    Jin Zhang, Shiyuan Liu, Danjie Zhang, Zhenchuan Ma, Liangzhang Sun
    Journal of Cellular Biochemistry.2019; 120(8): 13717.     CrossRef
  • Adjuvant radiotherapy for stage pN1M0 esophageal squamous cell carcinoma: Results from a Chinese two‐center study
    Wenjie Ni, Junqiang Chen, Zefen Xiao, Shufei Yu, Wencheng Zhang, Zongmei Zhou, Dongfu Chen, Qinfu Feng, Xiaohui Chen, Yu Lin, Kunshou Zhu, Shugeng Gao, Qi Xue, Yousheng Mao, Guiyu Cheng, Kelin Sun, Xiangyang Liu, Dekang Fang
    Thoracic Cancer.2019; 10(6): 1431.     CrossRef
  • Comparison of the effect of postoperative radiotherapy with surgery alone for esophagus squamous cell carcinoma patients
    Xiao-han Zhao, Duo Wang, Fang Wang, Shu-chai Zhu
    Medicine.2018; 97(47): e13168.     CrossRef
  • The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa–IVa lower thoracic oesophageal squamous cell carcinoma
    Yichun Wang, Liyang Zhu, Wanli Xia, Liming Wu, Fan Wang
    World Journal of Surgical Oncology.2018;[Epub]     CrossRef
  • A retrospective study of pattern of recurrence after radical surgery for thoracic esophageal carcinoma with or without postoperative radiotherapy
    Yichun Wang, Li Zhang, Dongmei Ye, Wanli Xia, Jun Jiang, Xiumei Wang, Mingxia Zhang, Fan Wang
    Oncology Letters.2018;[Epub]     CrossRef
  • Pattern of lymph node metastasis in thoracic esophageal squamous cell carcinoma with poor differentiation
    Jinling Zhang, Yuanyuan Liu, Fengyuan Che, Yi Luo, Wei Huang, Xueyuan Heng, Baosheng Li
    Molecular and Clinical Oncology.2018;[Epub]     CrossRef
  • Negative lymph node at station 108 is a strong predictor of overall survival in esophageal cancer
    Jinling Zhang, Xueyuan Heng, Yi Luo, Luning Li, Haiyan Zhang, Fengyuan Che, Baosheng Li
    Oncology Letters.2018;[Epub]     CrossRef
  • 10,423 View
  • 180 Download
  • 14 Web of Science
  • 12 Crossref
Close layer
A Feasibility Study of Adenosine Triphosphate-based Chemotherapy Response Assay (ATP-CRA) as a Chemosensitivity Test for Lung Cancer
Shin Myung Kang, Moo Suk Park, Joon Chang, Se Kyu Kim, Haeryoung Kim, Dong-Hwan Shin, Kyung Young Chung, Dae Joon Kim, Joo Hyuk Sohn, Sung Ho Choi, Jeongmi Kim, Eun Jin Yoon, Joo-Hang Kim
Cancer Res Treat. 2005;37(4):223-227.   Published online August 31, 2005
DOI: https://doi.org/10.4143/crt.2005.37.4.223
AbstractAbstract PDFPubReaderePub
Purpose

A chemosensitivity test can reflect the differences in responses of individual cancer patients to chemotherapeutic agents. The adenosine triphosphate-based chemotherapy response assay (ATP-CRA)is an accurate method, which does not require a large amount of tissue specimen. So far, no studies have evaluated the utility of the ATP-CRA in Korea. Therefore, we investigated the clinical usefulness of the ATP-CRA in 53 patients with lung cancer.

Materials and Methods

Tumor tissues were obtained from bronchoscopic biopsies or surgical resections. The validity of ATP-CRA was assessed focusing on the success rate, experimental error level (intraassay mean coefficient of variation [CV]) and reproducibility.

Results

The overall success rate of ATP-CRA was 90.6% (48/53). Normal cells were effectively eliminated from the tumor tissues with the use of ficoll gradient centrifugation and immunomagnetic separation, which was confirmed using loss of heterozygosity analysis of the 3p deletion. The mean CV of ATP assays was 10.5±4.6%. The reproducibility of ATP assays was 94±3.8%. The results of the ATP assays were reported to physicians within 7 days of specimen collection. More than 6 anticancer drugs were tested on the tumor specimens obtained from bronchoscopic biopsies.

Conclusion

The ATP-CRA is a stable, accurate and potentially practical chemosensitivity test in patients with lung cancer.

Citations

Citations to this article as recorded by  
  • In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer
    Hye Youn Kwon, Im-kyung Kim, Jeonghyun Kang, Seung-Kook Sohn, Kang Young Lee
    Cancer Research and Treatment.2016; 48(3): 970.     CrossRef
  • Correlation of Early Recurrence With In Vitro Adenosine Triphosphate Based Chemotherapy Response Assay in Pancreas Cancer With Postoperative Gemcitabine Chemotherapy
    Joon Seong Park, Jae Keun Kim, Dong Sup Yoon
    Journal of Clinical Laboratory Analysis.2016; 30(6): 804.     CrossRef
  • Clinical correlation between <i>in vitro</i> chemoresponse assay and first line chemotherapy for metastatic colorectal cancer patients
    Sang Hun Jung, So Hyun Kim, Jae Hwang Kim
    Korean Journal of Clinical Oncology.2015; 11(2): 51.     CrossRef
  • Association between Chemotherapy-Response Assays and Subsets of Tumor-Infiltrating Lymphocytes in Gastric Cancer: A Pilot Study
    Jee Youn Lee, Taeil Son, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh, Choong-Bai Kim, Chung-Gyu Park, Hyoung-Il Kim
    Journal of Gastric Cancer.2015; 15(4): 223.     CrossRef
  • ATP-Based Chemotherapy Response Assay in Primary or Recurrent Ovarian and Peritoneal Cancer
    Maria Lee, Sang Wun Kim, Eun Ji Nam, Hanbyoul Cho, Jae Hoon Kim, Young Tae Kim, Sunghoon Kim
    Yonsei Medical Journal.2014; 55(6): 1664.     CrossRef
  • Recent applications of chemosensitivity tests for colorectal cancer treatment
    Yong Sik Yoon
    World Journal of Gastroenterology.2014; 20(44): 16398.     CrossRef
  • Molecular portraits of intratumoral heterogeneity in human ovarian cancer
    Yoon Pyo Choi, Hyo Sup Shim, Ming-Qing Gao, Suki Kang, Nam Hoon Cho
    Cancer Letters.2011; 307(1): 62.     CrossRef
  • Chemotherapy Response Assay Test and Prognosis for Breast Cancer Patients Who Have Undergone Anthracycline- and Taxane-Based Chemotherapy
    Anbok Lee, Woosung Lim, Byung-In Moon, Nam-Sun Paik, Suck-Hwan Koh, Jeong-Yoon Song
    Journal of Breast Cancer.2011; 14(4): 283.     CrossRef
  • Adjuvant Chemotherapy Based on the In Vitro Histoculture Drug Response Assay for Non-small Cell Lung Cancer Improves Survival
    Masayuki Tanahashi, Hiroshi Niwa, Haruhiro Yukiue, Eriko Suzuki, Hiroshi Haneda, Naoko Yoshii
    Journal of Thoracic Oncology.2010; 5(9): 1376.     CrossRef
  • In VitroAdenosine Triphosphate Based Chemotherapy Response Assay in Gastric Cancer
    Seulkee Park, Yanghee Woo, Hogeun Kim, Yong Chan Lee, Sungho Choi, Woo Jin Hyung, Sung Hoon Noh
    Journal of Gastric Cancer.2010; 10(4): 155.     CrossRef
  • Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer
    Jee Hyun Kim, Keun-Wook Lee, Yeul Hong Kim, Kyung Hee Lee, Do Youn Oh, Joonhee Kim, Sung Hyun Yang, Seock-Ah Im, Sung Ho Choi, Yung-Jue Bang
    Journal of Korean Medical Science.2010; 25(5): 684.     CrossRef
  • In vitro chemosensitivity based on depth of invasion in advanced colorectal cancer using ATP-based chemotherapy response assay (ATP-CRA)
    Y.B. Cho, W.Y. Lee, S.Y. Song, S.H. Choi, H.J. Shin, K.-D. Ahn, J.M. Lee, H.C. Kim, S.H. Yun, H.-K. Chun
    European Journal of Surgical Oncology (EJSO).2009; 35(9): 951.     CrossRef
  • Heterogeneity of Adenosine Triphosphate-Based Chemotherapy Response Assay in Colorectal Cancer - Secondary Publication
    Jung Wook Huh, Yoon Ah Park, Kang Young Lee, Seung-Kook Sohn
    Yonsei Medical Journal.2009; 50(5): 697.     CrossRef
  • The use of an in vitro adenosine triphosphate-based chemotherapy response assay to predict chemotherapeutic response in breast cancer
    Hyun-Ah Kim, Cha-Kyong Yom, Byung-In Moon, Kuk-Jin Choe, Sun-Hee Sung, Woon-Sup Han, Hye-Young Choi, Hye-Kyoung Kim, Heung-Kyu Park, Sung-Ho Choi, Eun-Jin Yoon, Soo-Youn Oh
    The Breast.2008; 17(1): 19.     CrossRef
  • Predictive Value of Individualized Tumor Response Testing by ATP-Based Chemotherapy Response Assay in Ovarian Cancer
    Seung-Su Han, Sung Ho Choi, Yoo-Kyung Lee, Jae Weon Kim, Noh-Hyun Park, Yong-Sang Song, Hyo-Pyo Lee, Soon-Beom Kang
    Cancer Investigation.2008; 26(4): 426.     CrossRef
  • In-vitro Chemosensitivity Test for Colorectal Cancer using an Adenosine-triphosphate-based Chemotherapy Response Assay (ATP-CRA)
    Jung Wook Huh, Yoon Ah Park, Seung Kook Sohn, Sung Ho Choi
    Journal of the Korean Society of Coloproctology.2007; 23(3): 172.     CrossRef
  • Adenosine triphosphate‐based chemotherapy response assay (ATP‐CRA)‐guided platinum‐based 2‐drug chemotherapy for unresectable nonsmall‐cell lung cancer
    Yong Wha Moon, Sung Ho Choi, Yong Tai Kim, Joo Hyuk Sohn, Joon Chang, Se Kyu Kim, Moo Suk Park, Kyung Young Chung, Hyoun Ju Lee, Joo‐Hang Kim
    Cancer.2007; 109(9): 1829.     CrossRef
  • Preliminary Study of the Clinical Features of the Chemosensitivity Test in Colorectal Cancer
    Chan Sup Park, Sung Ho Choi, Hung Dai Kim
    Journal of the Korean Society of Coloproctology.2007; 23(5): 358.     CrossRef
  • Correlation between the In Vitro ATP-based Chemosensitivity Assay and HER2/neu Expression in Women with Breast Cancer
    SU Woo, JW Bae, HG Kim, SH Choi, DH Kang, JB Lee, BW Koo
    Journal of International Medical Research.2007; 35(6): 753.     CrossRef
  • 12,777 View
  • 53 Download
  • 19 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP